Compare TG Therapeutics Inc (TGTX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wynn Resorts, Limited — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Wynn Resorts, Limited trades at $90.51 (market cap $9.50B). The key difference: TG Therapeutics Inc and Wynn Resorts, Limited are close in size by market cap, and Wynn Resorts, Limited pays a 1.08% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WYNN | |
|---|---|---|
Market Cap | $8.53B | $9.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $133.34 |
52-Week Low | $26.94 | $90.23 |
Enterprise Value | $8.74B | $19.74B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, amid mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, though U.S. margins face pressure. Revenue reached $7.14B in 2025 with a net income margin of 4.58%, while debt remains elevated at $10.5B. Recent institutional buying includes Barrow Hanley's $321M investment, and analysts maintain a bullish consensus price target of $132.44.
Wynn's outlook is supported by Macau recovery and new project pipelines like Wynn Al Marjan, but high capital expenditure and debt load pose risks. The stock offers 44% upside to consensus target, though investors should monitor margin pressures and capex execution. Near-term support lies at $91, with resistance at $93.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
